A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (ATLANTIC)

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: April 19, 2011
Last updated: July 20, 2015
Last verified: July 2015

The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.

The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms:

re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.

or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.

Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI.

After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.

Condition Intervention Phase
Myocardial Infarction
Segment Elevation Myocardial Infarction (STEMI)
Drug: Ticagrelor
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint) [ Time Frame: At initial angiography, pre PCI ] [ Designated as safety issue: No ]
    (TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.

  • ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint) [ Time Frame: Between baseline and PCI ] [ Designated as safety issue: No ]
    ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (<70%) resolution.

Secondary Outcome Measures:
  • 1st Composite Clinical Endpoint [ Time Frame: during the 30 days of treatment ] [ Designated as safety issue: No ]
    death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death

  • 2nd Composite Clinical Endpoint [ Time Frame: within 30 days of study ] [ Designated as safety issue: No ]
    Death/MI/urgent revascularization. Adjudicated events except death

  • Definite Stent Thrombosis [ Time Frame: during 30 days of treatment ] [ Designated as safety issue: No ]
    Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint

  • TIMI Flow Grade 3 Post -PCI [ Time Frame: at coroangiography post-PCI ] [ Designated as safety issue: No ]
    TIMI) flow grade 3 is complete perfusion post-PCI.

  • ST Segment Elevation Resolution Post-PCI >= 70% [ Time Frame: Between baseline and ECG 60 mn post-PCI ] [ Designated as safety issue: No ]
    ST segment elevation resolution post PCI >=70% is defined as complete resolution

  • Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI [ Time Frame: during PCI ] [ Designated as safety issue: No ]
    Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.

  • Major Bleeds Within 48 Hours [ Time Frame: within 48 hours of first dose ] [ Designated as safety issue: No ]
    non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds

  • Minor and Major Bleedings Within 48 Hours [ Time Frame: within 48 hours of first dose ] [ Designated as safety issue: No ]
    non CABG related bleeds (PLATO definition)

  • Major Bleeds After 48 Hours [ Time Frame: after 48hours post-first dose ] [ Designated as safety issue: No ]
    non CABG related bleeds (PLATO definition) include life threatening and other major bleedings

  • Minor and Major Bleeds After 48 Hours [ Time Frame: after 48 hours post first dose ] [ Designated as safety issue: No ]
    non CABG related bleeds (PLATO definition)

Enrollment: 1875
Study Start Date: September 2011
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ticagrelor
Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
Drug: Ticagrelor
Oral Ticagrelor loading dose (180 mg) followed by matching placebo
Experimental: Placebo
Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
Drug: Placebo
Placebo followed by oral Ticagrelor loading dose (180 mg)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women must not be of child-bearing potential (1 year post-menopausal or surgically sterile).
  • Symptoms of acute MI of more than 30 min but less than 6 hours
  • New persistent ST-segment elevation ≥ 1 mm in two or more contiguous electrocardiogram (ECG) leads.

Exclusion Criteria:

  • Expected time to 1st PCI balloon inflation in the hospital, from the qualifying ECG is more than 120 minutes
  • Contraindication to ticagrelor (refer to SmPC)
  • Concomitant medication that may increase the risk of bleeding [e.g non steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulant and / or fibrinolytics, planned or administered 24 hours before randomization]
  • Any of the following conditions in the absence of a functioning implanted pacemaker: known SSS, second or third degree AVB, or documented syncope of suspected bradycardic origin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01347580

  Show 101 Study Locations
Sponsors and Collaborators
Study Director: Dr Judith Hsia, MD AstraZeneca
Principal Investigator: Pr Gilles Montalescot Pitie Salpetriere Hospital
  More Information

Additional Information:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01347580     History of Changes
Other Study ID Numbers: D5130L00006
Study First Received: April 19, 2011
Results First Received: November 13, 2014
Last Updated: July 20, 2015
Health Authority: Denmark: Danish Medicines Agency
Austria: Federal Office for Safety in Health Care
Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: The Italian Medicines Agency
Netherlands: Medicines Evaluation Board (MEB)
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Hungary: National Institute of Pharmacy
Australia: Queensland Health Authorities
Algeria: Ministère de la Santé, de la Population et de la Réforme Hospitalière

Keywords provided by AstraZeneca:
Heart attack
heart disease
cardiovascular disease
pre hospital settings
Percutaneous Coronary Intervention

Additional relevant MeSH terms:
Myocardial Infarction
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Pathologic Processes
Vascular Diseases
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists

ClinicalTrials.gov processed this record on December 01, 2015